"Analgesics in Belgium" now available at Fast Market Research

One of the categories to be most impacted by climatic conditions is analgesics. Belgians overconsume analgesics such as ibuprofen and acetaminophen in particular at the first sign of cold or flu symptoms. Sales of these products depend on ailments that are often treated with a mix of analgesics and vitamin C, for instance. Therefore, the exceptionally low temperatures of the winter 2015 was good news for analgesic manufacturers at the beginning of the year. It resulted in an immediate peak of pathologies, and thus sales of analgesics, which was not witnessed in 2014.

Competitive Landscape

In spite of its decline, UPSA Médica’s Dafalgan remained the absolute leading brand in analgesics with a 36% share in value in 2015. By virtue of its huge brand equity and its sales force, the brand’s nickname was previously the "road roller of analgesics" as it consistently gained ground until the middle of 2010-2015 period. Dafalgan was even the most valuable brand in the overall consumer health market in Belgium in 2015. However, from 2012 at least, the leading brand began to lose its influence on sales due to the offensive of contenders such as Nurofen and generics, which were more aggressive than the leader in the second half of the review period. In addition, UPSA Médica (GBO: Bristol Myers Squibb) did not really innovate before 2015, the year of its recovery, which coincided with some noteworthy novelties.

Full Report Details at
- http://www.fastmr.com/prod/1082053_analgesics_belgium.aspx?afid=301

Industry Prospects

The development of analgesics over the forecast period is set to continue to rely primarily on climatic conditions and on the fate of two brands, namely Dafalgan and Nurofen, which accounted for the bulk of value sales of branded products in systemic analgesics in 2015. After its recovery in 2015, marketing support and real innovations could help to restore the growth trajectory of Dafalgan after its slowdown in 2013/2014, and thus revitalise the competition with Nurofen, its main rival. Another notable aid could be consumers’ distrust of traditional Rx analgesics. The disaffection with some Rx pain inhibitors is expected to encourage more consumers to use OTC analgesics instead, particularly double-dose products, such as 1,000mg acetaminophen and 400mg ibuprofen. These products are considered less risky than the Rx alternatives. In addition, 1,000mg acetaminophen tablets achieve a satisfaction rate of 80%, which is much higher than for the 500mg format.

Report Overview

Discover the latest market trends and uncover sources of future market growth for the Analgesics industry in Belgium with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Analgesics in South Korea
- Analgesics in Tunisia
- Analgesics in the United Arab Emirates
- Analgesics in Mexico
- Analgesics in Algeria